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doi:10.1Objective: Although aprotinin has been widely used to reduce perioperative blood loss after cardiopulmonary by-
pass, recent concerns have led to its withdrawal. This study investigated effects of the novel synthetic serine protease
inhibitors CU-2010 and CU-2020 on blood loss, coagulation parameters, and coronary relaxation in a canine model.
Methods: Thirty-seven dogs were divided into 5 groups: control (n¼ 5), aprotinin (n¼ 8, Hammersmith scheme
of intravenous bolus, prime, and continuous infusion), Hammersmith CU-2010 (n¼ 8, 1.6 mg/kg Hammersmith
scheme), continuous CU-2010 (n¼ 8, 1.6 mg/kg continuous infusion), and CU-2020 (n¼ 8, 8.9 mg/kg Hammer-
smith scheme). All animals underwent 90-minute cardiopulmonary bypass. End points were blood loss during first
2 hours after protamine and activated clotting, partial thromboplastin, and prothrombin times. At end of experi-
ments, coronary rings were removed for in vitro testing of relaxation to acetylcholine and sodium nitroprusside.
Results: Hammersmith and continuous CU-2010, CU-2020, and aprotinin groups all had reduced blood loss
(43  4, 43  8, 52  7, 61  7, respectively, vs control 149  24 mL, P< .05). After protamine, activated
clotting time and partial thromboplastin time normalized in control, aprotinin, and Hammersmith CU-2010
groups but remained elevated in continuous CU-2010 and CU-2020 groups. Prothrombin time and vascular
relaxation did not differ between groups.
Conclusions: CU-2010 and CU-2020 significantly reduced blood loss after cardiac surgery, with prolonged partial
thromboplastin and activated clotting times, demonstrating improved antithrombotic profile. Neither aprotinin nor
the novel serine protease inhibitors influenced vascular relaxation. (J Thorac Cardiovasc Surg 2010;139:181-8)Excessive postoperative bleeding during cardiac surgery oc-
curs in 3.6% of patients undergoing coronary artery bypass
grafting and increases to 11% among those requiring more
complex operations.1,2 Reoperation for bleeding increases
hospital mortality 3- to 4-fold,1,2 substantially lengthens
postoperative hospital stay, and has a sizeable effect on
health care costs. Even without the need for reoperation,
blood loss frequently leads to transfusion of allogeneic
blood products, which exposes patients to risks of transfu-
sion-related adverse effects, including allergic reactions,
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Sabout transfusion safety, blood product shortages, and in-
creasing blood bank costs have generated growing interest
in risk-reduction strategies for postoperative bleeding.
The nonspecific serine protease inhibitor aprotinin was
formerly used to reduce the perioperative blood loss and
the need for blood transfusion after cardiopulmonary bypass
(CPB). Aprotinin is produced from bovine tissue, so the pos-
sibility of an allergic reaction must be considered whenever
this drug is used. The anaphylactic potential of aprotinin has
been a major concern; the overall risk of anaphylaxis to
aprotinin is estimated to be 0.5%, and even higher in reex-
posed patients at approximately 2.8%.3 Allergic or severe
anaphylactic reactions have been reported,4 although mainly
with reexposure. Because aprotinin is a bovine protein, the
possibility of an infectious disease is also raised. These con-
cerns have led to reduced use of aprotinin. Novel serine pro-
tease inhibitors have been in development for the following
reasons: (1) to simplify drug synthesis (aprotinin is isolated
from bovine lungs in a costly procedure), (2) to avoid the al-
lergic potential of the commercial aprotinin product (which
contains additional proteins that must be considered when-
ever this drug is used), and (3) to avoid the theoretic infec-
tious risks of bovine protein products. The compounds
tested in this study were developed to address these issues
while aiming at comparable blood loss reduction to
aprotinin.rdiovascular Surgery c Volume 139, Number 1 181
Abbreviations and Acronyms
ACT ¼ activated clotting time
aPTT ¼ activated partial thromboplastin time
CPB ¼ cardiopulmonary bypass
EC200 ¼ Concentration for 2-fold prolongation of
clotting time
Ki ¼ affinity constant
KIU ¼ kallikrein inactivator units
PT ¼ prothrombin time
SNP ¼ sodium nitroprusside
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SCU-2010 (Curacyte Discovery GmbH, Leipzig, Ger-
many) is a novel, small, synthetic compound (molecular
weight 700 Da) with peptidelike characteristics that allow
substratelike binding to the active site of serine proteases
(Katz and colleagues5 reviewed this class of compounds).
CU-2010 shows rapid clearance after intravenous infusion,
with an elimination half-life of approximately 20 minutes
in rats and dogs (unpublished animal experiment data,
Nicklisch S, Curacyte Discovery, January 2007). CU-2020
is the polymerized and pegylated form of CU-2010 with
a prolonged half-life (45 minutes).
In the past, our group has been involved in the develop-
ment of novel synthetic small-molecule serine protease in-
hibitors. The potential advantage of this new class of
serine protease inhibitors includes the elimination of allergic
and infectious risks and the reduction of thromboembolic
risk through improved antifibrinolytic and anticoagulatory
profiles. The primary aim of this study was to compare the
efficacy of the new synthetic serine protease inhibitors
CU-2010 and CU-2020 on curtailing blood loss with that
of bovine aprotinin in a canine model of extracorporeal cir-
culation. Special interest was focused on the issue whether
a simplified dosing scheme (simple continuous infusion)
would lead to the same effectiveness as the combination of
boluses and intravenous infusion.
Endothelial function and thrombus formation are closely
related. Injury of the endothelial surface leads to increased
rate of thrombus formation. Endothelial integrity is also
a key factor in regulation of blood flow and in defense
against inflammation or ischemia–reperfusion injury. The
vascular effects of aprotinin have only been partially clari-
fied. Many authors have shown that aprotinin causes graft
occlusion, especially venous graft occlusion6,7; however,
no clinical association between aprotinin use and graft oc-
clusion could be found in other studies.8 Experimental stud-
ies have resulted in conflicting data. Khan and colleagues9
have described favorable effects of aprotinin on endothelial
function in experimental model. There have been also
some experimental observations that aprotinin impairs
endothelium-dependent relaxation.10,11 The secondary aim182 The Journal of Thoracic and Cardiovascular Surgof our experiment was therefore to examine the effects of
aprotinin analogs on endothelium-dependent and -indepen-
dent vasorelaxation of coronary arteries and on coagulation
parameters.
MATERIALS AND METHODS
In Vitro Measurements
Serine protease inhibitory activities and corresponding affinity constant
(Ki) values were determined by standard enzyme kinetic assays and were
provided by the manufacturer (Curacyte Discovery; Tables 1 and 2).
Prothrombin time (PT) and activated partial thromboplastin time (aPTT)
were determined after standard human plasma (Dade Behring, Eschborn,
Germany) was supplemented with test compound solution or saline solution
with a coagulation analyzer (Sysmex CA-560; Dade Behring) according to
manufacturer instructions. Reagents used were Innovin for PT and Actin
FSL for aPTT, both from Dade Behring. Aprotinin was purchased from
Sigma (Sigma, St Louis, Mo). From each concentration–response curve,
EC200 values, defined as the concentration required for 2-fold prolongation
of clotting time, were calculated.
Animals
All animals received humane care and treatment in compliance with the
‘‘Principles of Laboratory Animal Care’’ formulated by the National Soci-
ety for Medical Research and in accordance with the ‘‘Guide for the Care
and Use of Laboratory Animals’’ (www.nap.edu/catalog/5140.html).
Power analysis to determine the necessary number of animals was based
on the primary end point of blood loss. We accepted an a error of .05 and
a b error of .15. Taking dropouts into account, 10 animals per group were
required for this study. The experiments were approved by the ethical
committee of the Land Baden-Wu¨rttemberg, Germany, for Animal
Experimentation. All together, 37 dogs (foxhounds) weighing 20 to 35 kg
were used in these experiments.
Surgical Preparation and General Management
The dogs were medicated in advance with propionylpromazine and anes-
thetized with a bolus of pentobarbital (15 mg/kg initial bolus and then 0.5
mg/[kg $ h] intravenously), paralyzed with pancuronium bromide (0.1
mg/kg as a bolus and then 0.2 mg/[kg $ h] intravenously), and endotra-
cheally intubated. The dogs were ventilated with a mixture of room air
and oxygen (inspired fraction of oxygen 60%) at a frequency of 12 to 15
breaths/min and a tidal volume starting at 15 mL/(kg $ min). The settings
were adjusted by maintaining arterial PCO2 between 35 and 40 mm Hg.
The femoral artery and vein were cannulated to record mean arterial pres-
sure and take blood samples for the analysis of blood gases, electrolytes,
pH, and parameters of blood coagulation. Basic intravenous volume substi-
tution was carried out with Ringer’s solution at a rate of 1 mL/(kg $ min). If
necessary, the rate of volume substitution was modified according to the
continuously controlled input–output balance to maintain hemodynamic
stability. According to the values of potassium, bicarbonate, and base ex-
cess, substitution included administration of potassium chloride and sodium
bicarbonate (8.4%). Neither catecholamines nor other hormonal or pressor
substances were administered. Rectal temperature and standard peripheral
electrocardiogram were monitored continuously.
After left anterolateral thoracotomy in the fourth intercostal space, peri-
cardiotomy, and isolation of the great vessels, a perivascular ultrasonic flow
probe was attached to the ascending aorta. Aortic pressure was monitored
with a 5F Millar catheter tip manometer (Millar Instruments Inc, Houston,
Tex).
Cardiopulmonary Bypass
After systemic anticoagulation with sodium heparin (300 U/kg), the left
subclavian artery was cannulated for arterial perfusion. The venous cannulaery c January 2010
TABLE 2. In vitro coagulation assay
CU-2010 CU-2020 Aprotinin
Activated partial
thromboplastin time EC200 (mmol/L)
1.4 32.8 11.9
Prothrombin time EC200 (mmol/L) 9.1 36.7 >100
EC200, Concentration required for 2-fold prolongation of clotting time.
TABLE 1. Inhibition of human serine proteases
CU-2010 CU-2020 Aprotinin
Plasmin 2.2 8.4 4.2
Plasma kallikrein 0.04 0.16 31
Factor Xa 51 81 218,000
Factor XIa 26 819 2687
Thrombin 1423 1553 164,000
Factor XIIa 4040 892 2951
Values are given in nanomoles per liter.
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exchanger, a venous reservoir, a roller pump, and a membrane oxygenator
primed with Ringer’s lactate solution (1000 mL) supplemented with heparin
(150 U/kg) and 20 mL sodium bicarbonate (8.4%). Normothermic CPB was
performed for 90 minutes. After weaning from CPB, heparin was antago-
nized with protamine administered intravenously during the course of 10
minutes, and the animals were monitored for 2 hours. Hearts and coronary
arteries were then excised for further investigation.
Experimental Groups
Thirty-seven dogs were divided into 5 experimental groups: control an-
imals (n ¼ 5) received placebo, the aprotinin treatment group (n ¼ 8) re-
ceived bovine aprotinin, and the remaining dogs received the new
synthetic aprotinin analogs CU-2010 (2 treatment schemes, n ¼ 8 each)
and CU-2020 (n ¼ 8). In the bovine-derived aprotinin group, the treatment
was applied according to the Hammersmith scheme (intravenous bolus,
pump prime, and continuous infusion) for a body weight of 30 kg, starting
with an intravenous bolus (0.85 million kallikrein inactivator units [KIU])
just before CPB was initiated, followed by a pump prime (0.85 million
KIU) and an infusion during CPB at a rate of 0.2 million KIU/h for 90
minutes (0.3 million KIU total). The applied dose of aprotinin was ad-
justed to the actual body weight of each animal. Accordingly, the animals
received 28,333 KIU/kg as an initial bolus and 28,333 KIU/kg in the
pump prime. During CPB, 10,000 KIU/kg aprotinin was infused during
90 minutes. Dogs receiving the aprotinin analog treatments were divided
three groups: the Hammersmith CU-2010 group received a 0.8 mg/kg bo-
lus before CPB, followed by a pump prime (0.4 mg/kg) and a continuous
infusion (0.4 mg/kg) during CPB (90 minutes); the continuous CU-2010
group received 1.6 mg/kg continuous infusion during the experiment
(220 minutes); and the CU-2020 group received a 1.66 mg/kg bolus be-
fore CPB, followed by a pump prime (1.66 mg/kg) and 4.98 mg/kg in-
fused during 90 minutes of CPB. The doses were selected primarily on
the basis of in vitro data, aiming for a dose more or less equipotential
with aprotinin. Furthermore, the observed half-life values (CU-2010 17
minutes, CU-2020 45 minutes) were taken into account in the selection
of the doses.
Measurements of Blood Loss and Biochemical and
Hemodynamic Parameters
The primary end point of the study was the total blood loss after weaning
from CPB during the first 2 hours after application of protamine. Blood loss
was measured from gauze bandages after weaning from CPB and 15 min-
utes after finishing of protamine at different time points (120, 160, and
220 minutes after initiation of CPB). Bandages were placed into the operat-
ing area (pericardial sac and surrounding tissues). Weight of gauze bandages
was measured before and after cleaning of the operating area. We calculated
blood loss from differences in weight of gauze bandages. The same numbers
of bandages (3 pieces at once) were removed every 10 minutes during the
first 30 minutes of the observation period and every 20 minutes thereafter
to standardize the blood loss measurement protocol and to avoid overfillingThe Journal of Thoracic and Caof the operative area with blood. Secondary end points were parameters of
coagulation (activated clotting time [ACT], prothrombin ratio (Quick
method), and aPTT). These parameters were monitored before CPB and be-
fore application of heparin and study medications, at 45 and 90 minutes of
CPB, and after weaning from CPB at 105 and 220 minutes from initiation of
CPB. ACT (celite method), prothrombin ratio, and PTT were assessed by
routine clinical assays. Heart rate and arterial pressure were monitored con-
tinuously.Vascular Function
Endothelium-dependent and –independent vasorelaxation responses
were investigated in isolated coronary arterial rings from the dogs. After
the end of the experiments, the coronary arteries were excised and placed
in cold (4C) Krebs–Henseleit solution (118-mmol/L sodium chloride,
4.7-mmol/L potassium chloride, 1.2-mmol/L potassium dihydrogen phos-
phate, 1.2-mmol/L magnesium sulfate, 1.77-mmol/L calcium chloride,
25-mmol/L sodium hydrogen carbonate, and 11.4-mmol/L glucose, pH
7.4). The coronary arteries were prepared, and cleansed of periadventitial
fat and surrounding connective tissue, and cut transversely into 4-mm rings
with an operation microscope. Rings from the left anterior descending and
circumflex coronary arteries were used randomly.
Isolated coronary rings were mounted on stainless steel hooks in individ-
ual organ baths (Radnoti Glass Technology, Monrovia, Calif) containing 25
mL of Krebs–Henseleit solution at 37C and aerated with 95% oxygen and
5% carbon dioxide. Special attention was paid during the preparation to
avoid damaging the endothelium.
Isometric contractions were recorded with isometric force transducers
(Radnoti Glass Technology). Data were digitized, stored, and displayed
with the IOX Software System (EMKA Technologies, Paris, France).
The coronary rings were placed under a resting tension of 3.5 g and
equilibrated for 60 minutes. During this period, tension was periodically ad-
justed to the desired level, and the Krebs–Henseleit solution was changed
every 30 minutes. Potassium chloride was used in these experiments to pre-
pare vessels for stable contractions and reproducible dose–response curves
to other vasoactive agents. Coronary rings were contracted with 80-mmol/L
potassium chloride and rinsed after the contraction until resting tension was
again obtained. The thromboxane A2–receptor agonist U46619 (5 3 10
7
mol/L) was used to contract the rings until a stable plateau was reached,
and relaxation responses were examined by adding cumulative concentra-
tions of the endothelium-dependent dilator acetylcholine (109–104 mol/
L) and the endothelium-independent dilator sodium nitroprusside (SNP,
1010–105 mol/L). Contractile responses are expressed as grams of tension,
relaxation responses are expressed as percentages of contraction induced by
U46619.Statistics
All values are expressed as mean  SEM. The paired t test was used to
compare 2 means within groups. Individual means were compared between
the groups by 1-way analysis of variance followed by an unpaired t test with
Bonferroni correction for multiple comparisons and the post hoc Scheffe´
test. In the figures, only the significant differences between groups are indi-
cated. Significant changes with the time within each group are indicated in
the text.rdiovascular Surgery c Volume 139, Number 1 183
FIGURE 1. In vitro activated partial thromboplastin time (aPTT) and prothrombin time (PT) values. Dose–response relationships.
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In Vitro Measurements
Table 1 shows Ki values of the inhibition of human serine
proteases. Plasmin inhibition was comparable between apro-
tinin and CU-2010 and CU-2020. Plasma kallikrein inhibition
potency, however, was 30-fold improved with the analogs, as
indicated by their markedly lower Ki values. In addition, CU-
2010 and CU-2020 have considerable (as much as 100,000
times greater than aprotinin) inhibitory potential of factor
Xa and factor XIa as well as thrombin. In vitro aPTT and cor-
responding EC200 values were similar for all 3 compounds.
Although application of aprotinin does not influence PT
values, there was a clear dose-dependent relationship when
CU-2010 or CU-2020 was applied (Figure 1 and Table 2).Hemodynamics During CPB
All animals were hemodynamically stable throughout the
experiments. Hemodynamic variables did not differ either
between the groups or with time. The time course of mean
arterial pressure is shown in Figure 2.Blood Loss
Postoperative blood loss during the first 2 hours after in-
jection of protamine was significantly reduced with184 The Journal of Thoracic and Cardiovascular SurgCU-2010 and CU-2020 as well as with aprotinin relative
to control (P< .05). There were no differences between
the 4 treatment groups (Figure 3).Blood Coagulation Parameters
As expected, aPTT and ACT increased significantly in all
groups after heparin and remained elevated during CPB
(Figures 4 and 5). After protamine administration, ACT re-
turned to baseline. Prothrombin ratio values decreased sig-
nificantly during CPB and remained low until the end of
the observation period (Figure 6). As shown in Figure 5,
treatment with CU-2010 (continuous infusion scheme) and
CU-2020 significantly elongated PTT after CPB at 105
and 220 minutes, respectively. There was also a tendency to-
ward prolonged ACT values, although this trend did not
reach the level of significance.Vascular Function
Maximal isometric forces produced by the isolated coro-
nary arterial rings contracted by the thromboxane A2–recep-
tor agonist U46619 (5 3 107 mol/L) were not significantly
altered in any of the experimental groups studied (data not
shown). The endothelium-dependent, receptor-mediated
vasorelaxation response of the precontracted coronaryery c January 2010
FIGURE 4. Activated clotting time (ACT). Time points indicate time in
minutes from initiation of cardiopulmonary bypass; T220 correspond to di-
rectly and 2 hours after protamine, respectively. All values are mean 
SEM. CU2010 (I.), Hammersmith CU-2010 group; CU2010 (II.), continu-
ous CU-2010 group.
FIGURE 2. Time course of mean arterial pressure. All values are mean 
SEM. Time points on x-axis indicate time in minutes from initiation of car-
diopulmonary bypass. CU2010 (I.), Hammersmith CU-2010 group;
CU2010 (II.), continuous CU-2010 group.
Szabo´ et al Evolving Technology/Basic Sciencearterial rings to acetylcholine was unaffected by all treat-
ments scheme with synthetic aprotinin analogs (Figure 7).
Application of the synthetic aprotinin analogs did not affect
the endothelium- and receptor-independent cyclic guanosine
monophosphate–mediated vasorelaxation response to SNP
(Figure 8).
DISCUSSION
In this study, 2 novel synthetic small-molecule serine pro-
tease inhibitors significantly reduced postoperative blood
loss after CPB comparably to aprotinin. In addition, neither
aprotinin nor the novel serine protease inhibitors affected
coronary endothelial function.FIGURE 3. Blood loss after weaning from cardiopulmonary bypass and
protamine. Time points indicate time in minutes from initiation of cardiopul-
monary bypass, corresponding to 20 (T130), 60 (T160), and 120 (T220)
minutes after protamine. All values are mean  SEM, Asterisk indicates
P < .05 versus control. CU2010 (I.), Hammersmith CU-2010 group;
CU2010 (II.), continuous CU-2010 group.
The Journal of Thoracic and CaApart from the concerns raised about possible side effects
of aprotinin, there is an evidence that aprotinin reduces post-
operative blood loss and transfusion requirements as much
as 40% to 50% in different population of patients (first
time, reoperative, patients with aspirin, etc) undergoing car-
diac surgery with CPB.12-14 Recently, significantly reduced
blood loss was reported after the use of aprotinin in patients
undergoing off-pump coronary artery bypass grafting.15
This study demonstrates for the first time that members of
a new class of synthetic small-molecule serine protease in-
hibitors (CU-2010 and CU-2020) significantly decrease
postoperative total blood loss after CPB in a canine model.FIGURE 5. Activated partial thromboplastin time (aPTT). Time points in-
dicate time in minutes from initiation of cardiopulmonary bypass; T105 and
T220 correspond to directly and 2 hours after protamine, respectively. All
values are mean  SEM. Asterisk indicates P<.05 versus control; grid re-
fers to P< .05 versus aprotinin. CU2010 (I.), Hammersmith CU-2010
group; CU2010 (II.), continuous CU-2010 group.
rdiovascular Surgery c Volume 139, Number 1 185
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FIGURE 6. Prothrombin ratio (Quick method) expressed as percentage of
reference plasma pool. Time points indicate time in minutes from initiation
of cardiopulmonary bypass; T105 and T220 correspond to directly and
2 hours after protamine, respectively. All values are mean  SEM.
CU2010 (I.), Hammersmith CU-2010 group; CU2010 (II.), continuous
CU-2010 group.
FIGURE 8. Endothelium-independent relaxation after application of so-
dium nitroprusside (SNP). CPB, Cardiopulmonary bypass; CU2010 (I.),
Hammersmith CU-2010 group; CU2010 (II.), continuous CU-2010 group.
All values are mean  SEM.
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significantly different with the tested doses and application
schemes.
These novel serine protease inhibitors may have some
potential advantages, which may also overcome some of
the concerns about the use of aprotinin that have led to its
withdrawal from the market. First, in contrast to the biologic
product aprotinin (a bovine peptide), CU-2010 and CU-
2020 are synthetic small molecules, and the well-known
allergic reaction described after the use of aprotinin3 can
therefore be reduced. The major cause of allergic reactions
after application of the aprotinin product Trasylol was notFIGURE 7. Endothelium-dependent relaxation after application of
acetylcholine (ACh). All values are mean  SEM. CPB, Cardiopulmonary
bypass; CU2010 (I.), Hammersmith CU-2010 group; CU2010 (II.), contin-
uous CU-2010 group.
186 The Journal of Thoracic and Cardiovascular Surgaprotinin itself but secondary bovine proteins and their frag-
ments, which were still present in low concentrations be-
cause 100% purity could not be achieved during the
manufacturing process from bovine lungs. These new com-
pounds are thus less likely to be allergenic, because they are
not natural products purified from an animal source.
Second, the novel protease inhibitors have a high antifibri-
nolytic potency complemented by moderate anticoagulatory
properties.16 In contrast to aprotinin, CU-2010 and CU-2020
have additional factor Xa and stronger factor XIa inhibitory
effects, which may protect against early thrombosis, one of
the concerns in connection with the use of aprotinin. Indeed,
in vitro tests have shown a significant dose-dependent
prolongation of PT after application of CU-2010 and
CU-2020, whereas aprotinin does not affect PT. In the our
experimental model, only a somewhat lower prothrombin
ratio (somewhat prolonged PT) was observed when
CU-2010 was applied as a continuous infusion or after Ham-
mersmith scheme application of CU-2020. It should be
noted, however, that CPB and hemodilution probably had
higher impacts on blood coagulation factors than did the fac-
tor Xa inhibitory effects of the test compounds themselves.
Further investigations are necessary. Nevertheless, aPTT
was still significantly prolonged after protamine in the
CU-2010 continuous infusion and CU-2020 groups,
whereas aPTT returned to baseline level in the other groups.
This implies that the additional inhibitory potential against
factors Xa and XIa provides an anticoagulatory potential
and may have a protective effect against early thrombosis.
It should be noted that even aprotinin may exert some antith-
rombotic effects.17,18
The observed differences in terms of blood coagulation
parameters between the dosage schemes of CU-2010 canery c January 2010
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minutes). After cessation of application of CU-2010, aPTT
values normalized rapidly. If the infusion was continued un-
til the end of the experiments, aPTT remained prolonged.
The very short half-life of CU-2010 might be advantageous
in allowing it to be used in an on-off switch mode, adapting
the application to the actual hemostatic situation. CU-2020
has a longer half-life (45 minutes), thereby providing pro-
longed aPTT when applied by the Hammersmith scheme.
Measurement of ACT is a standard monitoring procedure
for guidance of heparin-induced anticoagulation. Although
the optimum ACT value for CPB has not been established,
values between 400 and 480 seconds are commonly main-
tained. We applied the heparin doses according to the clini-
cal calculations, which resulted in higher ACT values than in
human beings. Nevertheless, application of protamine per-
formed accordingly resulted in a rapid normalization of
ACT levels in the control group. We therefore believe that
higher ACT values during CPB did not influence blood
loss after protamine significantly.
Initial investigations demonstrated that celite ACT values
are prolonged by aprotinin.19 The increase in ACT is artifi-
cial caused by an in vitro interaction of the celite activator,
heparin, and aprotinin. In contrast, aprotinin does not affect
kaolin ACT.20 We used a celite-based ACT in our experi-
ment, measured ACT values every 15 minutes, and main-
tained a value of more than 500 seconds during CPB. As
expected, aPTT and ACT increased significantly in all
groups after heparinization and remained elevated during
CPB. It should be noted, however, that in the previously
mentioned 2 treatment groups (continuous CU-2010, CU-
2020) ACT remained elevated in parallel with higher
aPTT values after protamine. Further studies are necessary
to determine whether the observed elevated ACT represents
a true anticoagulant property.
Vascular and in particular endothelial function is an im-
portant determinant of functional recovery after cardiac sur-
gery with CPB and early thrombus formation. In a recent
report,21 we showed for the first time in a clinically relevant
mammalian model of CPB that aprotinin has no significant
effect on vascular function in epicardial coronary arteries.
Previous investigations on the endothelial effects of aproti-
nin in other models have resulted in conflicting results. U¨lker
and coworkers10 found impaired endothelium-dependent
vasorelaxation to acetylcholine and to the calcium ionophore
A23187 in rat thoracic aortic rings and inhibition of brady-
kinin-induced endothelium-dependent coronary vasodilata-
tion in coronary arteries of rat Langendorff-perfused hearts
in the presence of aprotinin.11 In contrast to these findings,
Khan and colleagues9 reported aprotinin-induced improve-
ment of both endothelium-dependent and –independent vas-
orelaxation of coronary microvessels after regional ischemia
and cardioplegic arrest in a porcine model. These data are in
line with the results of Fischer and Steinhoff.22 With sub-The Journal of Thoracic and Castance P used to induce endothelium-dependent vasorelaxa-
tion, they found no significant effect of aprotinin at clinical
dosage levels on endothelial function in porcine coronar-
ies.22 Similar to our current results, endothelium-dependent
relaxation to acetylcholine was unaffected by aprotinin treat-
ment of human saphenous vein rings (explanted for coronary
bypass) in a previous study.23 In this study, we have ex-
tended previous findings and showed that these 2 novel ser-
ine protease inhibitors do no have any detrimental effect on
vascular relaxation, at least in vitro.
There have been only sporadic studies investigating the
effect of aprotinin on endothelium-independent dilatory
function of vascular smooth muscles. Most have reported
no influence of aprotinin on endothelium-independent vaso-
relaxation to SNP,10,11 a nitric oxide donor substance that
acts in a receptor-independent cyclic guanosine monophos-
phate–mediated manner by directly activating the guanylyl
cyclase enzyme in vascular smooth muscle cells. Our current
data completely correspond with these results; the SNP-in-
duced vasorelaxation of coronary arterial rings was unaf-
fected by aprotinin. Similarly, the novel serine protease
inhibitors did not influence vascular smooth muscle
function.
In conclusion, we have documented that the novel serine
protease inhibitors CU-2010 and CU-2020 equivalently re-
duce blood loss and have improved anticoagulatory proper-
ties relative to aprotinin. Taking into account that these small
synthetic molecules have numerous advantages relative to
aprotinin, we believe that these substances may offer
a true alternative in the postaprotinin era. Learning the les-
sons from the current debates, however, several safety trials
should performed before moving into the clinical arena.References
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Dr Craig R. Smith (New York, NY). First, I thank you for send-
ing me a manuscript a couple of weeks ago. That shows a high level
of organization.
It’s nice to bring compounds like this before us. It takes a lot of
courage to try to do something like this when you know that this
might work out very well but then 25 years from now somebody
will publish a paper in the New England Journal of Medicine show-
ing 100,000 patients in a meta-analysis with 0.2% increase in cre-
atinine with a P value of .00001, and you’ll be out of business.
You picked 2 drugs that are extremely potent as antikallikrein
agents. In the Ki tables, I gather you assume that the plasma Ki com-
pletely summarizes the drugs’ antifibrinolytic action. I’m not sure
that’s true, but perhaps it is. There may be other ways to directly
assess antifibrinolysis, which has usually been assumed to be the
main mechanism by which aprotinin reduces blood loss and has188 The Journal of Thoracic and Cardiovascular Surgspawned other antifibrinolytic agents, which you’re all familiar
with, tranexamic acid and aminocaproic acid. Can you tell us any-
thing about how your agents behave as antifibrinolytics, either with
plasma Ki or some more elaborate assessment of antifibrinolytic
activity?
Dr Szabo´. I only showed some examples of Ki values on human
serum proteases. And it’s true that plasmin activation is not the only
one mechanism in fibrinolysis.
We have also additional data where we additionally investigated
the effects of these new compounds on fibrinolysis. And we have
found, in terms of fibrinolysis, not really much difference from
aprotinin; but then the aim of designing this model was to have
something similar to aprotinin. What we did, and that was impor-
tant to show, was try to add some other protease inhibitory actions
in terms of improved anticoagulatory properties. As we showed in
terms of factors Xa and XIa, there are considerable gulatory prop-
erties in these drugs.
Dr Smith. That’s clearly an advantage of these drugs. But you
didn’t test their antifibrinolytic activity against tranexamic acid or
other agents that are more specific?
Dr Szabo´. No, just against aprotinin.
Dr Smith. Regarding my second question, I notice that you dis-
cussed celite in your manuscript. I’m still surprised that you chose
to use a celite activator, knowing it sets you up for questions from
somebody like me who will ask you about the celite-aprotinin inter-
action.
You assume, I gather, that the equivalence of ACTs in all the
groups means that there was no artificial elevation of ACT by apro-
tinin, but can you tell us what the heparin doses were?
Dr Szabo´. Well, in terms of celite ACT, I think that is an impor-
tant issue in terms of management in the human situation. In our
study, we could not document what we know from the clinical
arena, that aprotinin artificially prolongs ACTs. Nevertheless, we
used the normal human dose. It seems that dogs are more sensitive
to heparin, so we have much higher ACT values, longer than 1000
or 1500 seconds, and that might be why we could not document the
artificial prolongation of ACT in response to aprotinin. What we
saw is that the new compounds also prolonged PTT, which was
not prolonged by aprotinin. So we speculate that we have here
a true prolongation of blood coagulation, and not an artificial situ-
ation, also in terms of ACT. This would imply that it in a human
situation we would not need higher heparin doses for the patients.
Dr Smith. Since you didn’t actually answer the question about
what the heparin doses were in the different groups, I’ll just move
beyond that. But another way to look at that would be to look for
evidence of thrombin generation in all the groups, for a host of rea-
sons but one of them being to ensure that your ACTs were not in-
accurately reflecting the degree of anticoagulation.
Dr Pirooz Eghtesady (Cincinnati, Ohio). Did you look at renal
function or renal clearance of these drugs? Did you look at kidney
function?
Dr Szabo´. We have no data in this model about renal function.
The only related measurement was the urinary output during CPB,
primary with the aim of volume management, and we saw no dif-
ferences between the groups.ery c January 2010
